Health TrialsbyHealthPanel

Vascular Intervention Strategies Trial for Alzheimer's

ConditionsHypertensionHypercholesterolemiaDementia Risk Factors
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age50-75
SponsorUniversity of Southern California

About this trial

The proposed pharmacist-led study is a feasibility pilot trial for the management of vascular risk factors of hypertension and hypercholesterolemia in 10 APOE ε4 carriers, 50-75, at-risk for dementia. All participants will receive angiotensin receptor blockers (ARBs) for high blood pressure, and hydrophilic statins (or a non-statin alternative) for high cholesterol over a six-month period.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

APOE ε4 carrier (homozygote or heterozygote)

LDL-C of 100-250 mg/dL

Systolic blood Pressure (SBP) 130-180 mm Hg

Age 50-75 years

Disqualifiers

One minute standing SBP < 110 mm Hg

Arm circumference prevents from accurate BP measurement with use of available devices

Lost weight of > 10% unintendedly (within the past 6 months),

Contraindications to blood pressure and cholesterol lowering medications

Trial design

Design model

Single group

Treatments tested in this trial

  • Angiotensin Receptor Blockers (ARBs)

    Drug

    Participants receive pharmacist-led management of vascular risk factors over a six-month period. This includes blood pressure management with angiotensin receptor blockers (ARBs).

  • Hydrophilic Statins or Non-Statin Alternative

    Drug

    Participants receive pharmacist-led management of vascular risk factors over a six-month period. This includes cholesterol management with hydrophilic statins or a non-statin alternative if statins are not appropriate.

Treatment groups

10 Participants
are divided into 1 treatment group
Group A: Pharmacist-Led Vascular Risk Factor ManagementExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Blood Pressure Control

Change in systolic blood pressure (mmHg) from baseline to the end of the 6-month intervention.

Time frame
Baseline to 6 months

Secondary outcomes

1

Lipid Level Changes

Change in LDL cholesterol (mg/dL) from baseline to 6 months.

Time frame
Baseline to 6 months
2

Feasibility Metrics

adherence to prescribed medications (%).

Time frame
Study duration (6 months)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Southern California

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: